SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: September 20, 2004
VisiJet, Inc.
-------------
(Exact name of the Company as specified in its charter)
Delaware 0--256111 33-0838660
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
192 Technology Drive, Suite Q
Irvine, California 92618
(Address of principal executive offices)
The Company's telephone number, including area code:
949-453-9652
Section 8.01 Other Events
This Form 8-K is being furnished to report that on September 20, 2004,
VisiJet, Inc. issued a press release announcing that it has received FDA
approval to market its EpiLift System, a next-generation ophthalmic surgical
device designed for separating corneal tissue.
A copy of the press release is attached as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits
99.1 Press release dated September 20, 2004
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VisiJet, Inc., a Delaware
corporation
By: /s/ Laurence M. Schreiber
--------------------------------
Laurence M. Schreiber, Secretary
Date: September 20, 2004